140 related articles for article (PubMed ID: 32471182)
1. An Isoform of the Oncogenic Splice Variant AIMP2-DX2 Detected by a Novel Monoclonal Antibody.
Kim DG; Nguyen TTH; Kwon NH; Sung J; Lim S; Kang EJ; Lee J; Seo WY; Kim A; Chang YS; Shim H; Kim S
Biomolecules; 2020 May; 10(6):. PubMed ID: 32471182
[TBL] [Abstract][Full Text] [Related]
2. Allosteric Inhibition of the Tumor-Promoting Interaction Between Exon 2-Depleted Splice Variant of Aminoacyl-Transfer RNA Synthetase-Interacting Multifunctional Protein 2 and Heat Shock Protein 70.
Kim DG; Huddar S; Lim S; Kong J; Lee Y; Park CM; Lee S; Suh YG; Kim M; Lee K; Lee S; Kim S
J Pharmacol Exp Ther; 2021 Dec; 379(3):358-371. PubMed ID: 34503993
[TBL] [Abstract][Full Text] [Related]
3. Purification and biophysical characterization of the AIMP2-DX2 protein.
Jha R; Cho HY; Mushtaq AU; Lee K; Kim DG; Kim S; Jeon YH
Protein Expr Purif; 2017 Apr; 132():131-137. PubMed ID: 28185908
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Activity of Pyrimethamine via Ubiquitin Mediated Degradation of AIMP2-DX2.
Kim DG; Park CM; Huddar S; Lim S; Kim S; Lee S
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549310
[TBL] [Abstract][Full Text] [Related]
5. Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression.
Lee HS; Kim DG; Oh YS; Kwon NH; Lee JY; Kim D; Park SH; Song JH; Lee S; Han JM; Park BJ; Lee J; Kim S
Biochem J; 2013 Sep; 454(3):411-6. PubMed ID: 23815603
[TBL] [Abstract][Full Text] [Related]
6. Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer.
Jung JY; Kim EY; Kim A; Chang J; Kwon NH; Moon Y; Kang EJ; Sung JS; Shim H; Kim S; Chang YS
J Cancer; 2017; 8(8):1347-1354. PubMed ID: 28638448
[TBL] [Abstract][Full Text] [Related]
7. Rapid detection of exon 2-deleted AIMP2 mutation as a potential biomarker for lung cancer by molecular beacons.
Jo SM; Kim Y; Jeong YS; Hee Oh Y; Park K; Kim HS
Biosens Bioelectron; 2013 Aug; 46():142-9. PubMed ID: 23537880
[TBL] [Abstract][Full Text] [Related]
8. Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer.
Ku J; Kim R; Kim D; Kim D; Song S; Lee K; Lee N; Kim M; Yoon SS; Kwon NH; Kim S; Kim Y; Koh Y
Commun Biol; 2020 Oct; 3(1):630. PubMed ID: 33128014
[TBL] [Abstract][Full Text] [Related]
9. AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis.
Kim DG; Choi Y; Lee Y; Lim S; Kong J; Song J; Roh Y; Harmalkar DS; Lee K; Goo JI; Cho HY; Mushtaq AU; Lee J; Park SH; Kim D; Min BS; Lee KY; Jeon YH; Lee S; Lee K; Kim S
Nat Commun; 2022 May; 13(1):2572. PubMed ID: 35546148
[TBL] [Abstract][Full Text] [Related]
10. AIMP2-DX2 Promotes the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells.
Cao Q; Zhang J; Zhang T
Biomed Res Int; 2018; 2018():9253036. PubMed ID: 29854811
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral vector-mediated shRNA against AIMP2-DX2 suppresses lung cancer cell growth through blocking glucose uptake.
Chang SH; Chung YS; Hwang SK; Kwon JT; Minai-Tehrani A; Kim S; Park SB; Kim YS; Cho MH
Mol Cells; 2012 Jun; 33(6):553-62. PubMed ID: 22562359
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting DX2-p14/ARF Interaction Exerts Antitumor Effects in Lung Cancer and Delays Tumor Progression.
Oh AY; Jung YS; Kim J; Lee JH; Cho JH; Chun HY; Park S; Park H; Lim S; Ha NC; Park JS; Park CS; Song GY; Park BJ
Cancer Res; 2016 Aug; 76(16):4791-804. PubMed ID: 27302160
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug.
Lee B; Kim DG; Lee A; Kim YM; Cui L; Kim S; Choi I
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):51-66. PubMed ID: 36305287
[TBL] [Abstract][Full Text] [Related]
14. Discovery of benzodioxane analogues as lead candidates of AIMP2-DX2 inhibitors.
Lee B; Gyu Kim D; Mi Kim Y; Kim S; Choi I
Bioorg Med Chem Lett; 2022 Oct; 73():128889. PubMed ID: 35842206
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Structure-Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy.
Sivaraman A; Kim DG; Bhattarai D; Kim M; Lee HY; Lim S; Kong J; Goo JI; Shim S; Lee S; Suh YG; Choi Y; Kim S; Lee K
J Med Chem; 2020 May; 63(10):5139-5158. PubMed ID: 32315177
[TBL] [Abstract][Full Text] [Related]
16. Targeting the interaction of AIMP2-DX2 with HSP70 suppresses cancer development.
Lim S; Cho HY; Kim DG; Roh Y; Son SY; Mushtaq AU; Kim M; Bhattarai D; Sivaraman A; Lee Y; Lee J; Yang WS; Kim HK; Kim MH; Lee K; Jeon YH; Kim S
Nat Chem Biol; 2020 Jan; 16(1):31-41. PubMed ID: 31792442
[TBL] [Abstract][Full Text] [Related]
17. Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme.
Won YS; Lee SW
J Biotechnol; 2012 Mar; 158(1-2):44-9. PubMed ID: 22285955
[TBL] [Abstract][Full Text] [Related]
18. Anti-apoptotic Splicing Variant of AIMP2 Recover Mutant SOD1-Induced Neuronal Cell Death.
Kook MG; Byun MR; Lee SM; Lee MH; Lee DH; Lee HB; Lee EJ; Baek K; Kim S; Kang KS; Choi JW
Mol Neurobiol; 2023 Jan; 60(1):145-159. PubMed ID: 36242734
[TBL] [Abstract][Full Text] [Related]
19. Data on optimization of expression and purification of AIMP2-DX2 protein in
Jha R; Cho HY; Mushtaq AU; Lee K; Kim DG; Kim S; Jeon YH
Data Brief; 2017 Apr; 11():533-536. PubMed ID: 28367482
[TBL] [Abstract][Full Text] [Related]
20. Methionyl-tRNA synthetase and aminoacyl-tRNA synthetases interacting multi-functional protein-lacking exon 2 as potential diagnostic biomarkers for lung cancer.
Kim T; Lee K; Nahm JH; Kim EY; Lee SH; Chang YS
Am J Cancer Res; 2021; 11(6):3135-3144. PubMed ID: 34249450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
